RxDoctor Payments DataLook up a doctor →

Gail Wright, MD

Medical Oncology · Hudson, FLNPI 1669432290

Payments from drug & device makers

$13,788,073in general payments, 2019–2025

Across 2,037 payments — averaging $6768.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$8.3M
  • Seagen Inc.$1.3M
  • AstraZeneca$1.1M
  • Tesaro, Inc.$861K
  • Daiichi Sankyo Inc.$543K
  • Genentech, Inc.$391K
  • plus $1.3M from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis137$8,287,035
Seagen Inc.448$1,334,758
AstraZeneca(2 entities)72$1,116,690
Tesaro, Inc.38$861,334
Daiichi Sankyo Inc.149$542,832
Genentech, Inc.81$390,927
GSK112$365,943
E.r. Squibb & Sons, L.L.C.59$213,224
Taiho Oncology, Inc.86$185,420
Pfizer115$145,789
G1 Therapeutics, Inc.48$107,746
Eli Lilly25$104,525
Genmab U.S., Inc.1$51,505
AbbVie26$31,381
Macrogenics, Inc.31$30,478
Boehringer Ingelheim7$2,772
Immunogen, Inc.2$2,522
Astellas Pharma Global Development1$2,000
Johnson & Johnson(3 entities)70$1,291
Bristol Myers Squibb51$922
Gilead(2 entities)49$878
Merck35$641
Genentech USA, Inc.51$591
Takeda Pharmaceuticals U.S.A., Inc.14$461
Incyte Corporation23$453
Sanofi23$429
Lilly USA, LLC21$424
Bayer21$369
Exelixis Inc.20$313
Regeneron Healthcare Solutions, Inc.12$274
Tersera Therapeutics LLC9$274
Amgen15$242
Beigene USA, Inc.14$231
Eisai Inc.11$227
Astellas Pharma US Inc11$190
Pharmacyclics LLC, An Abbvie Company8$188
Puma Biotechnology, Inc.11$188
Organon2$178
Array Biopharma Inc9$167
Blueprint Medicines Corporation10$157
EMD Serono, Inc.8$118
Mirati Therapeutics, Inc.5$107
Octapharma USA, Inc.1$90
Deciphera Pharmaceuticals Inc.5$89
Jazz Pharmaceuticals Inc.5$88
Sirtex Medical Inc1$88
Sobi, Inc5$87
Pharmaessentia USA Corporation4$87
Legend Biotech USA Inc.3$76
Ipsen Biopharmaceuticals, Inc4$69
Tempus AI, Inc3$68
AVEO Pharmaceuticals, Inc.4$65
Rigel Pharmaceuticals, Inc.5$61
Beone Medicines USA, Inc.2$61
Myriad Genetic Laboratories, Inc.4$60
Springworks Therapeutics, Inc.2$53
Pharmacosmos Therapeutics Inc.3$52
Medtronic1$51
Dova Pharmaceuticals3$51
Morphosys, US Inc.3$50

How this compares

$13,788,073 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$2,850,479
Medicare patients
637
Services billed
117,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Hudson

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →